Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
NCT03175679
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL:
iNKT cells
DRUG:
IL-2
DRUG:
Tegafur
Sponsor
Beijing YouAn Hospital